2 weeks Ago By ABMN Staff
Wave Life Sciences Ltd. ( NASDAQ:WVE – Get Free Report ) major shareholder Plc Gsk acquired 2,791,930 shares of the stock in a transaction on Friday, September 27th. The stock was bought at an average price of $8.
00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528.
The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink . Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC. Wave Life Sciences Stock Performance WVE traded up $0.
10 during midday trading on Tuesday, reaching $8.30. 1,152,767 shares of the company were exchanged, compared to its average volume of 988,589.
The stock has a market capitalization of $1.02 billion, a P/E ratio of -15.81 and a beta of -1.
13. The stock’s 50-day simple moving average is $6.07 and its 200 day simple moving average is $5.
85. Wave Life Sciences Ltd. has a one year low of $3.
50 and a one year high of $9.92. Wave Life Sciences ( NASDAQ:WVE – Get Free Report ) last released its quarterly earnings results on Thursday, August 8th.
The company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.
09). The company had revenue of $19.69 million during the quarter, compared to analyst estimates of $24.
80 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 1,395.
99%. During the same quarter last year, the company earned ($0.20) EPS.
On average, research analysts anticipate that Wave Life Sciences Ltd. will post -1.04 earnings per share for the current year.
Institutional Inflows and Outflows Wall Street Analyst Weigh In Several research firms recently weighed in on WVE. Mizuho restated an “outperform” rating and issued a $19.00 price objective on shares of Wave Life Sciences in a research report on Tuesday, June 25th.
HC Wainwright upped their price target on Wave Life Sciences from $15.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, September 25th.
JPMorgan Chase & Co. initiated coverage on Wave Life Sciences in a report on Friday. They issued an “overweight” rating and a $13.
00 price target on the stock. Finally, B. Riley began coverage on Wave Life Sciences in a report on Thursday, September 19th.
They set a “buy” rating and a $11.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock.
Based on data from MarketBeat, Wave Life Sciences currently has a consensus rating of “Moderate Buy” and an average price target of $13.75. Check Out Our Latest Research Report on Wave Life Sciences About Wave Life Sciences ( Get Free Report ) Wave Life Sciences Ltd.
, a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Featured Articles Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
